FDAnews Drug Daily Bulletin

SCHERING MAY HAVE TO PAY TO PROTECT BETASERON

Dec. 12, 2005
A A

Schering AG, Germany's third-largest drugmaker, may have to buy rights to its Betaseron medicine to protect its single biggest source of revenue amid delays on new products such as the YAZ contraceptive. The Berlin-based drugmaker may exercise an option to buy the multiple sclerosis medicine back from Chiron Corp., which makes it in the U.S., now that Swiss rival Novartis AG is buying Chiron, spokesman Oliver Renner in a telephone interview today. He declined to say how much this may cost.

Bloomberg (http://www.bloomberg.com/apps/news?pid=10000085&sid=ac2AEw7BbXoA&refer=europe)